1,092 reports of this reaction
4.8% of all EPOPROSTENOL SODIUM reports
#1 most reported adverse reaction
DYSPNOEA is the #1 most commonly reported adverse reaction for EPOPROSTENOL SODIUM, manufactured by GlaxoSmithKline LLC. There are 1,092 FDA adverse event reports linking EPOPROSTENOL SODIUM to DYSPNOEA. This represents approximately 4.8% of all 22,890 adverse event reports for this drug.
Patients taking EPOPROSTENOL SODIUM who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among EPOPROSTENOL SODIUM users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for EPOPROSTENOL SODIUM:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 1,092 FDA reports for EPOPROSTENOL SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 4.8% of all adverse event reports for EPOPROSTENOL SODIUM, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking EPOPROSTENOL SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.